Evidence map›Paper›PMID 40958617›Full record

ArticleAnnals of medicine2025

Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.

Yifan Wu, Yaohui Wang, Xiaonan Sheng, Yanping Lin, Liheng Zhou, Jinsong Lu, Wenjin Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yifan WuDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.
Yaohui WangDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.
Xiaonan ShengDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.
Yanping LinDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.
Liheng ZhouDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.
Jinsong LuDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.ORCID 0000-0003-3874-9108
Wenjin YinDepartment of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.ORCID 0000-0002-2129-7443

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe conducted a retrospective exploratory analysis of prospective cohort to investigate the impact of CYP2A6 metabolizer status on predicting the efficacy and prognosis of neoadjuvant chemotherapy combined with letrozole.

methodThree allelic variants that related to the abolished or reduced activity of CYP2A6 enzyme and 7 other single nucleotide polymorphisms (SNPs) in the CYP2A6 locus were examined from whole blood samples before neoadjuvant treatment, and patients were classified into 3 metabolizer status subgroups ('normal', 'intermediate' and 'slow' metabolizers) according to CYP2A6 genotypes.

resultOur study included 56 patients received neoadjuvant chemotherapy combined with letrozole. The pCR rate in the CYP2A6 intermediate/slow metabolizers (29.2%) was higher than that in the normal metabolizers (12.5%;

conclusionThe CPY2A6 gene polymorphism may be a novel potential predictive and prognostic biomarker for postmenopausal hormone receptor-positive breast cancer patients receiving neoadjuvant chemotherapy combined with letrozole. Our findings have clinical implications for guiding precision endocrine therapy in hormone receptor-positive breast cancer patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCytochrome P-450 CYP2A6LetrozoleAdultAgedFemaleGenotypeHumansMiddle AgedNeoadjuvant TherapyPolymorphism, Single NucleotidePrognosisProspective StudiesReceptors, EstrogenRetrospective StudiesCYP2A6 protein, humanCytochrome P-450 CYP2A6LetrozoleReceptors, EstrogenTriazolesBreast cancerCYP2A6gene polymorphismletrozoleneoadjuvant therapy

Identifiers

PMID40958617
PMCPMC12444925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.